{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:57:20Z","timestamp":1785387440132,"version":"3.55.0"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Healthcare providers should balance the potential risks and benefits of chronic diuretic use, particularly in older adults, as with age, diuretic benefits may decline and risks increase. A comprehensive synthesis and critical evaluation of the available evidence on chronic diuretic treatment effects is currently lacking.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted an umbrella review of systematic reviews and meta-analyses published since 2018 on health outcomes associated with diuretic use in randomized-controlled trials (RCTs). We conducted random-effects meta-analysis for pooled effect estimates and narratively summarized data that could not be pooled.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We included 741 effect estimations from 117 systematic reviews (SRs) on 1566 RCTs in individuals aged 62\u2009\u00b1\u20096\u00a0years. Of our 33 meta-analyses, 11 provided convincing, high-quality evidence: finerenone reduced the risk of cardiovascular (CV) mortality and end-stage kidney disease in individuals with chronic kidney disease (CKD) and\/or type 2 diabetes (T2D). Torasemide reduced the risk of heart failure-related hospitalization (HFH) more than furosemide in individuals with HF. Thiazides reduced CV events in individuals with hypertension. Mineralocorticoid receptor antagonists (MRAs) reduced HFH, but also increased hyperkalemia risk in individuals with HF. MRAs also reduced the risk of atrial fibrillation in those with HF or CVD, and reduced HFH, major adverse cardiovascular events (MACEs),\u2009>\u200940% eGFR decrease, and composite kidney outcomes in individuals with CKD and\/or T2D. Lower quality evidence suggests that in older (\u2265\u200965\u00a0years), but not in younger adults, diuretics may reduce CV mortality, but also increase adverse event (AE) risk.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our umbrella review offers a comprehensive and up-to-date evaluation of the benefits and harms of diuretics. However, further research is needed to establish their efficacy and safety in populations commonly seen in clinical practice, especially older adults living with multimorbidity and frailty.<\/jats:p>\n <\/jats:sec>\n \n Graphical abstract<\/jats:title>\n <\/jats:sec>","DOI":"10.1007\/s41999-025-01229-5","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T10:48:57Z","timestamp":1748170137000},"page":"1353-1387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness and safety of chronic diuretic use in older adults: an umbrella review of recently published systematic reviews and meta-analyses of randomized-controlled trials"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-5602","authenticated-orcid":false,"given":"Eveline","family":"van Poelgeest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Prokopidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8690-0189","authenticated-orcid":false,"given":"Tu\u011fba","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2778-3984","authenticated-orcid":false,"given":"Min Ji","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4760-8588","authenticated-orcid":false,"given":"Karolina","family":"Piotrowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-9456","authenticated-orcid":false,"given":"Annette","family":"Eidam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6447-2352","authenticated-orcid":false,"given":"Fatma \u00d6zge Kayhan","family":"Ko\u00e7ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6039-5866","authenticated-orcid":false,"given":"Birkan","family":"Ilhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Beccacece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2291-5733","authenticated-orcid":false,"given":"George","family":"Soulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0994-1152","authenticated-orcid":false,"given":"Serdar","family":"\u00d6zk\u00f6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5343-9795","authenticated-orcid":false,"given":"Gulistan","family":"Bahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6786-4116","authenticated-orcid":false,"given":"Eva","family":"Topinkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8025-4961","authenticated-orcid":false,"given":"Joost","family":"Daams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-7865","authenticated-orcid":false,"given":"M. Louis","family":"Handoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8025-5323","authenticated-orcid":false,"given":"Jerzy","family":"G\u0105sowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0261-9897","authenticated-orcid":false,"given":"Antonio","family":"Cherubini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9328-289X","authenticated-orcid":false,"given":"Nicola","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9157-3781","authenticated-orcid":false,"given":"Giuseppe Dario","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"van der Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"European Geriatric Medicine Society Special Interest Groups of i. Pharmacology; ii. Cardiovascular Disease and iii. Systematic Review and Meta-analysis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"issue":"11","key":"1229_CR1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/eurheartj\/ehac810","volume":"44","author":"L Filbey","year":"2023","unstructured":"Filbey L, Zhu JW, D\u2019Angelo F, Thabane L, Khan MS, Lewis E et al (2023) Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum. Eur Heart J 44(11):921\u2013930. https:\/\/doi.org\/10.1093\/eurheartj\/ehac810","journal-title":"Eur Heart J"},{"issue":"5","key":"1229_CR2","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/jgs.16353","volume":"68","author":"PP Coll","year":"2020","unstructured":"Coll PP, Roche V, Olsen JS, Voit JH, Bowen E, Kumar M (2020) The prevention of cardiovascular disease in older adults. J Am Geriatr Soc 68(5):1098\u20131106. https:\/\/doi.org\/10.1111\/jgs.16353","journal-title":"J Am Geriatr Soc"},{"issue":"19","key":"1229_CR3","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.jacc.2018.03.022","volume":"71","author":"DE Forman","year":"2018","unstructured":"Forman DE, Maurer MS, Boyd C, Brindis R, Salive ME, Home FM et al (2018) Multimorbidity in older adults with cardiovascular disease. J Am Coll Cardiol 71(19):2149\u20132161. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.022","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1229_CR4","first-page":"684","volume":"378","author":"DH Ellison","year":"2018","unstructured":"Ellison DH, Felker GM (2018) Diuretic treatment in heart failure. New Engl J Med 378(7):684\u2013685","journal-title":"New Engl J Med"},{"key":"1229_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008161.pub3","volume":"7","author":"M Reinhart","year":"2023","unstructured":"Reinhart M, Puil L, Salzwedel DM, Wright JM (2023) First-line diuretics versus other classes of anti-hypertensive drugs for hypertension. Cochrane Database Syst Rev 7:ARTN CD008161. https:\/\/doi.org\/10.1002\/14651858.CD008161.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"1229_CR6","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2022","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS (2022) Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 118(17):3272\u20133287. https:\/\/doi.org\/10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"issue":"5","key":"1229_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155948","volume":"11","author":"FT Bourgeois","year":"2016","unstructured":"Bourgeois FT, Olson KL, Tse T, Ioannidis JPA, Mandl KD (2016) Prevalence and characteristics of interventional trials conducted exclusively in elderly persons: a cross-sectional analysis of registered clinical trials. PLoS ONE 11(5):ARTN e0155948. https:\/\/doi.org\/10.1371\/journal.pone.0155948","journal-title":"PLoS ONE"},{"issue":"1","key":"1229_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10741-018-9735-7","volume":"24","author":"J Simonavicius","year":"2019","unstructured":"Simonavicius J, Knackstedt C, Brunner-La Rocca HP (2019) Loop diuretics in chronic heart failure: how to manage congestion? Heart Fail Rev 24(1):17\u201330. https:\/\/doi.org\/10.1007\/s10741-018-9735-7","journal-title":"Heart Fail Rev"},{"issue":"9","key":"1229_CR9","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.amjmed.2021.04.007","volume":"134","author":"S Ravioli","year":"2021","unstructured":"Ravioli S, Bahmad S, Funk GC, Schwarz C, Exadaktylos A, Lindner G (2021) Risk of electrolyte disorders, syncope, and falls in patients taking thiazide diuretics: results of a cross-sectional study. Am J Med 134(9):1148\u20131154. https:\/\/doi.org\/10.1016\/j.amjmed.2021.04.007","journal-title":"Am J Med"},{"issue":"4","key":"1229_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/bcp.12499","volume":"79","author":"J Barber","year":"2015","unstructured":"Barber J, McKeever TM, McDowell SE, Clayton JA, Ferner RE, Gordon RD et al (2015) A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation? Br J Clin Pharmacol 79(4):566\u2013577. https:\/\/doi.org\/10.1111\/bcp.12499","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1229_CR11","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00392-020-01598-w","volume":"109","author":"JM Ter Maaten","year":"2020","unstructured":"Ter Maaten JM, Martens P, Damman K, Dickstein K, Ponikowski P, Lang CC et al (2020) Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clin Res Cardiol 109(8):1048\u20131059. https:\/\/doi.org\/10.1007\/s00392-020-01598-w","journal-title":"Clin Res Cardiol"},{"issue":"24","key":"1229_CR12","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/eurheartj\/ehx035","volume":"38","author":"W Mullens","year":"2017","unstructured":"Mullens W, Verbrugge FH, Nijst P, Tang WHW (2017) Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. Eur Heart J 38(24):1872\u20131882. https:\/\/doi.org\/10.1093\/eurheartj\/ehx035","journal-title":"Eur Heart J"},{"issue":"3","key":"1229_CR13","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/ehf2.13859","volume":"9","author":"D Tomasoni","year":"2022","unstructured":"Tomasoni D, Vishram-Nielsen JKK, Pagnesi M, Adamo M, Lombardi CM, Gustafsson F et al (2022) Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Fail 9(3):1507\u20131523. https:\/\/doi.org\/10.1002\/ehf2.13859","journal-title":"ESC Heart Fail"},{"issue":"8","key":"1229_CR14","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/ejhf.1796","volume":"22","author":"CJ Kapelios","year":"2020","unstructured":"Kapelios CJ, Laroche C, Crespo-Leiro MG, Anker SD, Coats AJS, D\u00edaz-Molina B et al (2020) Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. Eur J Heart Fail 22(8):1424\u20131437. https:\/\/doi.org\/10.1002\/ejhf.1796","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"1229_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s40266-023-01061-1","volume":"40","author":"C Okoye","year":"2023","unstructured":"Okoye C, Mazzarone T, Cargiolli C, Guarino D (2023) Discontinuation of loop diuretics in older patients with chronic stable heart failure: a narrative review. Drug Aging 40(11):981\u2013990. https:\/\/doi.org\/10.1007\/s40266-023-01061-1","journal-title":"Drug Aging"},{"issue":"4","key":"1229_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5770\/cgj.v14i4.19","volume":"14","author":"R Sztramko","year":"2011","unstructured":"Sztramko R, Chau V, Wong R (2011) Adverse drug events and associated factors in heart failure therapy among the very elderly. Can Geriatr J 14(4):79\u201392. https:\/\/doi.org\/10.5770\/cgj.v14i4.19","journal-title":"Can Geriatr J"},{"key":"1229_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.734045","volume":"12","author":"M Kurczewska-Michalak","year":"2021","unstructured":"Kurczewska-Michalak M, Lewek P, Jankowska-Polanska B, Giardini A, Granata N, Maffoni M et al (2021) Polypharmacy management in the older adults: a scoping review of available interventions. Front Pharmacol 12:ARTN 734045. https:\/\/doi.org\/10.3389\/fphar.2021.734045","journal-title":"Front Pharmacol"},{"key":"1229_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/CIA.S9564","volume":"5","author":"RL Page","year":"2010","unstructured":"Page RL, Linnebur SA, Bryant LL, Ruscin JM (2010) Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. Clin Interv Aging 5:75\u201387","journal-title":"Clin Interv Aging"},{"issue":"2","key":"1229_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/14740338.2017.1265503","volume":"16","author":"D Stewart","year":"2017","unstructured":"Stewart D, Mair A, Wilson M, Kardas P, Lewek P, Alonso A et al (2017) Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments. Expert Opin Drug Saf 16(2):203\u2013213. https:\/\/doi.org\/10.1080\/14740338.2017.1265503","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1229_CR20","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1097\/Mjt.0000000000001644","volume":"31","author":"S Fosnight","year":"2024","unstructured":"Fosnight S, Soric MM, Smearman J, Graves E, Vazquez M, Herrington Z et al (2024) Investigation into potentially inappropriate prescribing patterns of loop diuretics in a nationally representative outpatient population. Am J Ther 31(4):e347\u2013e355. https:\/\/doi.org\/10.1097\/Mjt.0000000000001644","journal-title":"Am J Ther"},{"issue":"1","key":"1229_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afab205","volume":"51","author":"BA Damoiseaux-Volman","year":"2022","unstructured":"Damoiseaux-Volman BA, Raven K, Sent D, Medlock S, Romijn JA, Abu-Hanna A et al (2022) Potentially inappropriate medications and their effect on falls during hospital admission. Age Ageing 51(1):ARTN afab205. https:\/\/doi.org\/10.1093\/ageing\/afab205","journal-title":"Age Ageing"},{"issue":"2","key":"1229_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211947","volume":"14","author":"CH Huang","year":"2019","unstructured":"Huang CH, Umegaki H, Watanabe Y, Kamitani H, Asai A, Kanda S et al (2019) Potentially inappropriate medications according to STOPP-J criteria and risks of hospitalization and mortality in elderly patients receiving home-based medical services. PLoS ONE 14(2):ARTN e0211947. https:\/\/doi.org\/10.1371\/journal.pone.0211947","journal-title":"PLoS ONE"},{"issue":"3","key":"1229_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/ageing\/afx178","volume":"47","author":"D O'Mahony","year":"2018","unstructured":"O\u2019Mahony D, O\u2019Sullivan D, Byrne S, O\u2019Connor MN, Ryan C, Gallagher P (2018) STOPP\/START criteria for potentially inappropriate prescribing in older people: version 2 (vol 44, pg 213, 2015). Age Ageing 47(3):489. https:\/\/doi.org\/10.1093\/ageing\/afx178","journal-title":"Age Ageing"},{"issue":"6","key":"1229_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jamda.2013.02.002","volume":"14","author":"M Wehling","year":"2013","unstructured":"Wehling M (2013) Morbus diureticus in the elderly: epidemic overuse of a widely applied group of drugs. J Am Med Dir Assoc 14(6):437\u2013442. https:\/\/doi.org\/10.1016\/j.jamda.2013.02.002","journal-title":"J Am Med Dir Assoc"},{"key":"1229_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1430","volume":"373","author":"C Carmona","year":"2021","unstructured":"Carmona C, Crutwell J, Burnham M, Polak L, Comm G (2021) Shared decision-making: summary of NICE guidance. BMJ-Br Med J. 373:ARTN n1430. https:\/\/doi.org\/10.1136\/bmj.n1430","journal-title":"BMJ-Br Med J."},{"issue":"1","key":"1229_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jgs.18681","volume":"72","author":"A Ndai","year":"2024","unstructured":"Ndai A, Al Bahou J, Morris E, Wang HM, Marcum Z, Hung A et al (2024) Mapping potentially inappropriate medications in older adults using the Anatomical Therapeutic Chemical (ATC) classification system. J Am Geriatr Soc 72(1):126\u2013138. https:\/\/doi.org\/10.1111\/jgs.18681","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"1229_CR27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","volume":"175","author":"IA Scott","year":"2015","unstructured":"Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D et al (2015) Reducing inappropriate polypharmacy the process of deprescribing. JAMA Intern Med 175(5):827\u2013834. https:\/\/doi.org\/10.1001\/jamainternmed.2015.0324","journal-title":"JAMA Intern Med"},{"issue":"6","key":"1229_CR28","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s41999-023-00872-0","volume":"14","author":"E van Poelgeest","year":"2023","unstructured":"van Poelgeest E, Seppala L, Bahat G, Ilhan B, Mair A, van Marum R et al (2023) Optimizing pharmacotherapy and deprescribing strategies in older adults living with multimorbidity and polypharmacy: EuGMS SIG on pharmacology position paper. Eur Geriatr Med 14(6):1195\u20131209. https:\/\/doi.org\/10.1007\/s41999-023-00872-0","journal-title":"Eur Geriatr Med"},{"key":"1229_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16189","author":"E van Poelgeest","year":"2024","unstructured":"van Poelgeest E, Paoletti L, \u00d6zk\u00f6k S, Pinar E, Bahat G, Vuong V et al (2024) The effects of diuretic deprescribing in adult patients: a systematic review to inform an evidence-based diuretic deprescribing guideline. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.16189","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1229_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11897-024-00643-3","volume":"21","author":"JJ Cuthbert","year":"2024","unstructured":"Cuthbert JJ, Clark AL (2024) Diuretic treatment in patients with heart failure: current evidence and future directions\u2014Part I: loop diuretics. Curr Heart Fail Rep 21(2):101\u2013114. https:\/\/doi.org\/10.1007\/s11897-024-00643-3","journal-title":"Curr Heart Fail Rep"},{"issue":"2","key":"1229_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57498","volume":"8","author":"R Vidonscky Luthold","year":"2025","unstructured":"Vidonscky Luthold R, Jungo KT, Weir KR, Adler L, Asenova R, Ares-Blanco S et al (2025) Older adults\u2019 attitudes toward deprescribing in 14 countries. JAMA Netw Open 8(2):e2457498. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57498","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1229_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/ajh\/hpae139","volume":"38","author":"CS Wilcox","year":"2024","unstructured":"Wilcox CS, Pourafshar N, Han KRA, Shah SZN, Sussman RD, Testani J et al (2024) Bladder symptoms provoked by short, rapid-acting loop diuretics: a frequent but often overlooked problem. Am J Hypertens 38(2):100\u2013103. https:\/\/doi.org\/10.1093\/ajh\/hpae139","journal-title":"Am J Hypertens"},{"issue":"10","key":"1229_CR33","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10(10):ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142","journal-title":"Cochrane Database Syst Rev"},{"key":"1229_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070849","volume":"378","author":"M Gates","year":"2022","unstructured":"Gates M, Gates A, Pieper D, Fernandes RM, Tricco AC, Moher D et al (2022) Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ-Br Med J. 378:ARTN e070849. https:\/\/doi.org\/10.1136\/bmj-2022-070849","journal-title":"BMJ-Br Med J."},{"key":"1229_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian R, Laird N (2015) Meta-analysis in clinical trials revisited. Contemp Clin Trials 45:139\u2013145. https:\/\/doi.org\/10.1016\/j.cct.2015.09.002","journal-title":"Contemp Clin Trials"},{"issue":"9","key":"1229_CR36","doi-asserted-by":"publisher","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","volume":"127","author":"J Lau","year":"1997","unstructured":"Lau J, Ioannidis JPA, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820\u2013826. https:\/\/doi.org\/10.7326\/0003-4819-127-9-199711010-00008","journal-title":"Ann Intern Med"},{"issue":"11","key":"1229_CR37","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186","journal-title":"Stat Med"},{"issue":"5","key":"1229_CR38","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/ije\/dyn204","volume":"37","author":"JPT Higgins","year":"2008","unstructured":"Higgins JPT (2008) Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 37(5):1158\u20131160. https:\/\/doi.org\/10.1093\/ije\/dyn204","journal-title":"Int J Epidemiol"},{"key":"1229_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","volume":"172","author":"JPT Higgins","year":"2009","unstructured":"Higgins JPT, Thompson SG, Spiegelhalter DJ (2009) A re-evaluation of random-effects meta-analysis. J Roy Stat Soc Ser A-Stat Soc 172:137\u2013159. https:\/\/doi.org\/10.1111\/j.1467-985X.2008.00552.x","journal-title":"J Roy Stat Soc Ser A-Stat Soc"},{"issue":"1","key":"1229_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/jrsm.1390","volume":"11","author":"EA Hennessy","year":"2020","unstructured":"Hennessy EA, Johnson BT (2020) Examining overlap of included studies in meta-reviews: guidance for using the corrected covered area index. Res Synth Methods 11(1):134\u2013145. https:\/\/doi.org\/10.1002\/jrsm.1390","journal-title":"Res Synth Methods"},{"issue":"5","key":"1229_CR41","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/jrsm.1658","volume":"14","author":"M Kirvalidze","year":"2023","unstructured":"Kirvalidze M, Abbadi A, Dahlberg L, Sacco LB, Calder\u00f3n-Larra\u00f1aga A, Morin L (2023) Estimating pairwise overlap in umbrella reviews: considerations for using the corrected covered area (CCA) index methodology. Res Synth Methods 14(5):764\u2013767. https:\/\/doi.org\/10.1002\/jrsm.1658","journal-title":"Res Synth Methods"},{"issue":"3","key":"1229_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jrsm.1557","volume":"13","author":"J P\u00e9rez-Bracchiglione","year":"2022","unstructured":"P\u00e9rez-Bracchiglione J, Meza N, Bangdiwala SI, de Guzm\u00e1n EN, Urr\u00fatia G, Bonfill X et al (2022) Graphical representation of overlap for OVErviews: GROOVE tool. Res Synth Methods 13(3):381\u2013388. https:\/\/doi.org\/10.1002\/jrsm.1557","journal-title":"Res Synth Methods"},{"issue":"7650","key":"1229_CR43","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.ad","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 336(7650):924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.ad","journal-title":"Br Med J"},{"key":"1229_CR44","doi-asserted-by":"publisher","first-page":"CD000028","DOI":"10.1002\/14651858.cd000028.pub3","volume":"6","author":"VM Musini","year":"2019","unstructured":"Musini VM, Tejani AM, Bassett K, Puil L, Wright JM (2019) Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database Syst Rev 6:CD000028. https:\/\/doi.org\/10.1002\/14651858.cd000028.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"1229_CR45","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jch.13598","volume":"21","author":"J Zhang","year":"2019","unstructured":"Zhang J, Tong A, Dai Y, Niu J, Yu F, Xu F (2019) Comparative risk of new-onset diabetes mellitus for anti-hypertensive drugs in elderly: a Bayesian network meta-analysis. J Clin Hypertens (Greenwich) 21(8):1082\u20131090. https:\/\/doi.org\/10.1111\/jch.13598","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"1229_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5853\/jos.2020.02698","volume":"23","author":"XL Zhong","year":"2021","unstructured":"Zhong XL, Dong Y, Xu W, Huang YY, Wang HF, Zhang TS et al (2021) Role of blood pressure management in stroke prevention: a systematic review and network meta-analysis of 93 randomized controlled trials. J Stroke 23(1):1\u201311. https:\/\/doi.org\/10.5853\/jos.2020.02698","journal-title":"J Stroke"},{"issue":"8","key":"1229_CR47","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1097\/hjh.0000000000001777","volume":"36","author":"C Thomopoulos","year":"2018","unstructured":"Thomopoulos C, Parati G, Zanchetti A (2018) Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14\u2014effects of different classes of anti-hypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens 36(8):1637\u20131647. https:\/\/doi.org\/10.1097\/hjh.0000000000001777","journal-title":"J Hypertens"},{"key":"1229_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.119.013267","author":"J Alexandre","year":"2019","unstructured":"Alexandre J, Dolladille C, Douesnel L, Font J, Dabrowski R, Shavit L et al (2019) Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta-analysis, and meta-regression to identify modifying factors. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/jaha.119.013267","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"1229_CR49","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1161\/hypertensionaha.123.21496","volume":"80","author":"Z Bidel","year":"2023","unstructured":"Bidel Z, Nazarzadeh M, Canoy D, Copland E, Gerdts E, Woodward M et al (2023) Sex-specific effects of blood pressure lowering pharmacotherapy for the prevention of cardiovascular disease: an individual participant-level data meta-analysis. Hypertension 80(11):2293\u20132302. https:\/\/doi.org\/10.1161\/hypertensionaha.123.21496","journal-title":"Hypertension"},{"issue":"11","key":"1229_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10683","volume":"6","author":"LC Desbiens","year":"2022","unstructured":"Desbiens LC, Khelifi N, Wang YP, Lavigne F, Beaulieu V, Sidibe A et al (2022) Thiazide diuretics and fracture risk: a systematic review and meta-analysis of randomized clinical trials. JBMR Plus 6(11):e10683. https:\/\/doi.org\/10.1002\/jbm4.10683","journal-title":"JBMR Plus"},{"key":"1229_CR51","doi-asserted-by":"publisher","first-page":"1236008","DOI":"10.3389\/fcvm.2023.1236008","volume":"10","author":"C Geng","year":"2023","unstructured":"Geng C, Mao YC, Qi SF, Song K, Wang HF, Zhang ZY et al (2023) Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat. Front Cardiovasc Med 10:1236008. https:\/\/doi.org\/10.3389\/fcvm.2023.1236008","journal-title":"Front Cardiovasc Med"},{"issue":"35","key":"1229_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000011942","volume":"97","author":"S Li","year":"2018","unstructured":"Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X et al (2018) Effects of spironolactone in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 97(35):e11942. https:\/\/doi.org\/10.1097\/md.0000000000011942","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1229_CR53","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/hypertensionaha.120.16397","volume":"77","author":"A Sakima","year":"2021","unstructured":"Sakima A, Arima H, Matayoshi T, Ishida A, Ohya Y (2021) Effect of mineralocorticoid receptor blockade on arterial stiffness and endothelial function: a meta-analysis of randomized trials. Hypertension 77(3):929\u2013937. https:\/\/doi.org\/10.1161\/hypertensionaha.120.16397","journal-title":"Hypertension"},{"issue":"1","key":"1229_CR54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12916-020-01530-z","volume":"18","author":"A Seeley","year":"2020","unstructured":"Seeley A, Prynn J, Perera R, Street R, Davis D, Etyang AO (2020) Pharmacotherapy for hypertension in Sub-Saharan Africa: a systematic review and network meta-analysis. BMC Med 18(1):75. https:\/\/doi.org\/10.1186\/s12916-020-01530-z","journal-title":"BMC Med"},{"issue":"8","key":"1229_CR55","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2215\/cjn.12201019","volume":"15","author":"AM Shaman","year":"2020","unstructured":"Shaman AM, Smyth B, Arnott C, Palmer SC, Mihailidou AS, Jardine MJ et al (2020) Comparative efficacy and safety of BP-lowering pharmacotherapy in patients undergoing maintenance dialysis: a network meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol 15(8):1129\u20131138. https:\/\/doi.org\/10.2215\/cjn.12201019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1229_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000534366","volume":"55","author":"CY Yuan","year":"2024","unstructured":"Yuan CY, Gao YC, Lin Y, Liu L, Shen XG, Zou WL et al (2024) Effects of mineralocorticoid receptor antagonists for chronic kidney disease: a systemic review and meta-analysis. Am J Nephrol 55(1):1\u201317. https:\/\/doi.org\/10.1159\/000534366","journal-title":"Am J Nephrol"},{"key":"1229_CR57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40265-024-02092-7","volume":"23","author":"X Yi","year":"2024","unstructured":"Yi X, Yang S, Yang J, Chen X, Zhang A, Zeng Q et al (2024) Renin-angiotensin-aldosterone system modulators in adults with hypertension: a network meta-analysis of randomized controlled trials. Drugs 23:23. https:\/\/doi.org\/10.1007\/s40265-024-02092-7","journal-title":"Drugs"},{"issue":"10","key":"1229_CR58","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002276","volume":"4","author":"ST Hardy","year":"2015","unstructured":"Hardy ST, Loehr LR, Butler KR, Chakladar S, Chang PP, Folsom AR et al (2015) Reducing the blood pressure-related burden of cardiovascular disease: impact of achievable improvements in blood pressure prevention and control. J Am Heart Assoc 4(10):ARTN e002276. https:\/\/doi.org\/10.1161\/JAHA.115.002276","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"1229_CR59","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1161\/01.Hyp.14.5.570","volume":"14","author":"J Stamler","year":"1989","unstructured":"Stamler J, Rose G, Stamler R, Elliott P, Dyer A, Marmot M (1989) Intersalt study findings\u2014public-health and medical-care implications. Hypertension 14(5):570\u2013577. https:\/\/doi.org\/10.1161\/01.Hyp.14.5.570","journal-title":"Hypertension"},{"key":"1229_CR60","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/j.ejim.2018.08.015","volume":"57","author":"P Shah","year":"2018","unstructured":"Shah P, Patel H, Mithawala P, Doshi R (2018) Torsemide versus furosemide in heart failure patients: a meta-analysis of randomized controlled trials. Eur J Intern Med 57:e38\u2013e40. https:\/\/doi.org\/10.1016\/j.ejim.2018.08.015","journal-title":"Eur J Intern Med"},{"issue":"4","key":"1229_CR61","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","volume":"105","author":"A Levin","year":"2024","unstructured":"Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK et al (2024) Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns. Kidney Int 105(4):684\u2013701. https:\/\/doi.org\/10.1016\/j.kint.2023.10.016","journal-title":"Kidney Int"},{"issue":"6","key":"1229_CR62","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/archinternmed.2011.31","volume":"171","author":"A Cherubini","year":"2011","unstructured":"Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G et al (2011) The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 171(6):550\u2013556","journal-title":"Arch Intern Med"},{"issue":"2","key":"1229_CR63","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/jgs.15785","volume":"67","author":"CB Bowling","year":"2019","unstructured":"Bowling CB, Whitson HE, Johnson TM (2019) The preliminary development of a framework to support inclusion of older adults in research. J Am Geriatr Soc 67(2):342\u2013346. https:\/\/doi.org\/10.1111\/jgs.15785","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"1229_CR64","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/jamacardio.2020.0359","volume":"5","author":"AS Tahhan","year":"2020","unstructured":"Tahhan AS, Vaduganathan M, Greene SJ, Alrohaibani A, Raad M, Gafeer M et al (2020) Enrollment of older patients, women, and racial\/ethnic minority groups in contemporary acute coronary syndrome clinical trials a systematic review. JAMA Cardiol 5(6):714\u2013722. https:\/\/doi.org\/10.1001\/jamacardio.2020.0359","journal-title":"JAMA Cardiol"},{"issue":"2","key":"1229_CR65","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1161\/Hypertensionaha.117.10391","volume":"71","author":"K Nanba","year":"2018","unstructured":"Nanba K, Vaidya A, Rainey WE (2018) Aging and adrenal aldosterone production. Hypertension 71(2):218\u2013223. https:\/\/doi.org\/10.1161\/Hypertensionaha.117.10391","journal-title":"Hypertension"},{"issue":"8","key":"1229_CR66","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2019.11.062","volume":"75","author":"MR Hamczyk","year":"2020","unstructured":"Hamczyk MR, Nevado RM, Barettino A, Fuster V, Andr\u00e9s V (2020) Biological versus chronological aging. Focus seminar. J Am Coll Cardiol 75(8):919\u2013930. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.062","journal-title":"J Am Coll Cardiol"},{"key":"1229_CR67","doi-asserted-by":"crossref","unstructured":"Zmora R, Schreiner PJ, Appiah D, Lloyd-Jones DM, Rana JS, Lewis CE (2017) Clinical risk factors related to biological versus chronological heart age: the coronary artery risk development in young adults (CARDIA) study. In: Circulation, vol 135.\u00a0Lippincott Williams & Wilkins,\u00a0Philadelphia","DOI":"10.1161\/circ.135.suppl_1.p239"},{"issue":"2","key":"1229_CR68","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026850","volume":"12","author":"A Aidoud","year":"2023","unstructured":"Aidoud A, Gana W, Poitau F, Debacq C, Leroy V, Nkodo JA et al (2023) High prevalence of geriatric conditions among older adults with cardiovascular disease. J Am Heart Assoc 12(2):ARTN e026850. https:\/\/doi.org\/10.1161\/JAHA.122.026850","journal-title":"J Am Heart Assoc"},{"key":"1229_CR69","doi-asserted-by":"publisher","DOI":"10.1161\/circ.150.suppl_1.4146141","author":"K Tom-Ayegunle","year":"2024","unstructured":"Tom-Ayegunle K, Tcheugui JE, Oshozimhede IE, Orkaby A, Kwak MJ, Goyal P et al (2024) The association of geriatric syndromes with cardiovascular disease: insights from ARIC visit 5 on cardiovascular risks in older adults. Circulation. https:\/\/doi.org\/10.1161\/circ.150.suppl_1.4146141","journal-title":"Circulation"},{"issue":"3","key":"1229_CR70","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/jep.13261","volume":"26","author":"NA Sherif","year":"2020","unstructured":"Sherif NA, Morra ME, Thanh LV, Elsayed GG, Elkady AH, Elshafay A et al (2020) Torasemide versus furosemide in treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials. J Eval Clin Pract 26(3):842\u2013851. https:\/\/doi.org\/10.1111\/jep.13261","journal-title":"J Eval Clin Pract"},{"issue":"21","key":"1229_CR71","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1161\/Cir.0000000000000380","volume":"133","author":"MW Rich","year":"2016","unstructured":"Rich MW, Chyun DA, Skolnick AH, Alexander KP, Forman DE, Kitzman DW et al (2016) Knowledge gaps in cardiovascular care of the older adult population: a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society. Circulation 133(21):2103\u20132122. https:\/\/doi.org\/10.1161\/Cir.0000000000000380","journal-title":"Circulation"},{"issue":"11","key":"1229_CR72","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/jamainternmed.2020.2750","volume":"180","author":"MG Nanna","year":"2020","unstructured":"Nanna MG, Chen ST, Nelson AJ, Navar AM, Peterson ED (2020) Representation of older adults in cardiovascular disease trials since the inclusion across the lifespan policy. Jama Intern Med 180(11):1531\u20131533. https:\/\/doi.org\/10.1001\/jamainternmed.2020.2750","journal-title":"Jama Intern Med"},{"issue":"1","key":"1229_CR73","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/acer.15229","volume":"48","author":"JD Wallach","year":"2024","unstructured":"Wallach JD, Glick L, Gueorguieva R, O\u2019Malley SS (2024) Evidence of subgroup differences in meta-analyses evaluating medications for alcohol use disorder: an umbrella review. Alcohol Clin Exp Res (Hoboken) 48(1):5\u201315. https:\/\/doi.org\/10.1111\/acer.15229","journal-title":"Alcohol Clin Exp Res (Hoboken)"},{"issue":"3","key":"1229_CR74","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ebmental-2018-300014","volume":"21","author":"P Fusar-Poli","year":"2018","unstructured":"Fusar-Poli P, Radua J (2018) Ten simple rules for conducting umbrella reviews. Evid-Based Ment Health 21(3):95\u2013100. https:\/\/doi.org\/10.1136\/ebmental-2018-300014","journal-title":"Evid-Based Ment Health"},{"issue":"10305","key":"1229_CR75","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","volume":"398","author":"K Rahimi","year":"2021","unstructured":"Rahimi K, Bidel Z, Nazarzadeh M, Copland E, Canoy D, Wamil M et al (2021) Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 398(10305):1053\u20131064. https:\/\/doi.org\/10.1016\/S0140-6736(21)01921-8","journal-title":"Lancet"},{"issue":"6","key":"1229_CR76","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1001\/jama.2021.12134","volume":"326","author":"MA Steinman","year":"2021","unstructured":"Steinman MA, Boyd CM, Schmader KE (2021) Expanding evidence for clinical care of older adults beyond clinical trial traditions and finding new approaches. JAMA-J Am Med Assoc 326(6):475\u2013476. https:\/\/doi.org\/10.1001\/jama.2021.12134","journal-title":"JAMA-J Am Med Assoc"},{"key":"1229_CR77","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2020.01008","author":"B Abdelazeem","year":"2022","unstructured":"Abdelazeem B, Elbadawy MA, Awad AK, Kheiri B, Kunadi A (2022) The cardiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: a meta-analysis of randomized clinical trials. Intractable Rare Dis Res. https:\/\/doi.org\/10.5582\/irdr.2020.01008","journal-title":"Intractable Rare Dis Res"},{"issue":"1","key":"1229_CR78","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.amjcard.2019.09.039","volume":"125","author":"B Abraham","year":"2020","unstructured":"Abraham B, Megaly M, Sous M, Fransawyalkomos M, Saad M, Fraser R et al (2020) Meta-analysis comparing torsemide versus furosemide in patients with heart failure. Am J Cardiol 125(1):92\u201399. https:\/\/doi.org\/10.1016\/j.amjcard.2019.09.039","journal-title":"Am J Cardiol"},{"key":"1229_CR79","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejim.2023.04.021","volume":"113","author":"M Ahmed","year":"2023","unstructured":"Ahmed M, Nudy M, Bussa R, Filippone EJ, Foy AJ (2023) A systematic review and meta-analysis of all sham and placebo controlled trials for resistant hypertension. Eur J Intern Med 113:83\u201390. https:\/\/doi.org\/10.1016\/j.ejim.2023.04.021","journal-title":"Eur J Intern Med"},{"key":"1229_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n189","volume":"372","author":"A Albasri","year":"2021","unstructured":"Albasri A, Hattle M, Koshiaris C, Dunnigan A, Paxton B, Fox SE et al (2021) Association between anti-hypertensive treatment and adverse events: systematic review and meta-analysis. BMJ 372:n189. https:\/\/doi.org\/10.1136\/bmj.n189","journal-title":"BMJ"},{"issue":"12","key":"1229_CR81","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1097\/hjh.0000000000002187","volume":"37","author":"ME Alexandrou","year":"2019","unstructured":"Alexandrou ME, Papagianni A, Tsapas A, Loutradis C, Boutou A, Piperidou A et al (2019) Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 37(12):2307\u20132324. https:\/\/doi.org\/10.1097\/hjh.0000000000002187","journal-title":"J Hypertens"},{"issue":"3","key":"1229_CR82","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40292-024-00646-0","volume":"31","author":"M Al-Sadawi","year":"2024","unstructured":"Al-Sadawi M, Tao M, Dhaliwal S, Goldschmit M, Tam E, Mann N (2024) Safety and efficacy of anti-hypertensive medications in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. High Blood Press Cardiovasc Prev 31(3):239\u2013249. https:\/\/doi.org\/10.1007\/s40292-024-00646-0","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"12","key":"1229_CR83","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1111\/bcp.14927","volume":"87","author":"IG Asiimwe","year":"2021","unstructured":"Asiimwe IG, Pushpakom S, Turner RM, Kolamunnage-Dona R, Jorgensen AL, Pirmohamed M (2021) Cardiovascular drugs and COVID-19 clinical outcomes: a living systematic review and meta-analysis. Br J Clin Pharmacol 87(12):4534\u20134545. https:\/\/doi.org\/10.1111\/bcp.14927","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1229_CR84","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00228-022-03408-w","volume":"78","author":"W Bao","year":"2022","unstructured":"Bao W, Zhang M, Li N, Yao Z, Sun L (2022) Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. Eur J Clin Pharmacol 78(12):1877\u20131887. https:\/\/doi.org\/10.1007\/s00228-022-03408-w","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1229_CR85","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10741-018-9689-9","volume":"23","author":"G Bazoukis","year":"2018","unstructured":"Bazoukis G, Thomopoulos C, Tse G, Tsioufis C (2018) Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis. Heart Fail Rev 23(4):547\u2013553. https:\/\/doi.org\/10.1007\/s10741-018-9689-9","journal-title":"Heart Fail Rev"},{"issue":"5","key":"1229_CR86","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/hjh.0000000000001671","volume":"36","author":"G Bazoukis","year":"2018","unstructured":"Bazoukis G, Thomopoulos C, Tsioufis C (2018) Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension. J Hypertens 36(5):987\u2013994. https:\/\/doi.org\/10.1097\/hjh.0000000000001671","journal-title":"J Hypertens"},{"issue":"2","key":"1229_CR87","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10741-018-9679-y","volume":"23","author":"KO Bonsu","year":"2018","unstructured":"Bonsu KO, Arunmanakul P, Chaiyakunapruk N (2018) Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison. Heart Fail Rev 23(2):147\u2013156. https:\/\/doi.org\/10.1007\/s10741-018-9679-y","journal-title":"Heart Fail Rev"},{"issue":"2","key":"1229_CR88","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10741-021-10207-5","volume":"27","author":"A Boulmpou","year":"2022","unstructured":"Boulmpou A, Theodorakopoulou MP, Alexandrou ME, Boutou AK, Papadopoulos CE, Pella E et al (2022) Meta-analysis addressing the impact of cardiovascular-acting medication on peak oxygen uptake of patients with HFpEF. Heart Fail Rev 27(2):609\u2013623. https:\/\/doi.org\/10.1007\/s10741-021-10207-5","journal-title":"Heart Fail Rev"},{"key":"1229_CR89","doi-asserted-by":"publisher","first-page":"1338044","DOI":"10.3389\/fphar.2024.1338044","volume":"15","author":"Q Chen","year":"2024","unstructured":"Chen Q, Wei G, Wang Y, Li X, Zhao Q, Zhu L et al (2024) Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials. Front Pharmacol 15:1338044. https:\/\/doi.org\/10.3389\/fphar.2024.1338044","journal-title":"Front Pharmacol"},{"issue":"3","key":"1229_CR90","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.hlc.2023.12.013","volume":"33","author":"KM Clark","year":"2024","unstructured":"Clark KM, Mahboob F, Evans J, Sun JH, Wang N (2024) Efficacy of guideline-directed medical therapy in heart failure patients with and without chronic kidney disease: a meta-analysis of 63,677 patients. Heart Lung Circ 33(3):281\u2013291. https:\/\/doi.org\/10.1016\/j.hlc.2023.12.013","journal-title":"Heart Lung Circ"},{"issue":"11","key":"1229_CR91","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41371-019-0255-2","volume":"33","author":"S Dineva","year":"2019","unstructured":"Dineva S, Uzunova K, Pavlova V, Filipova E, Kalinov K, Vekov T (2019) Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis. J Hum Hypertens 33(11):766\u2013774. https:\/\/doi.org\/10.1038\/s41371-019-0255-2","journal-title":"J Hum Hypertens"},{"key":"1229_CR92","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/mbp.0000000000000486","volume":"04","author":"S Dineva","year":"2020","unstructured":"Dineva S, Uzunova K, Pavlova V, Filipova E, Kalinov K, Vekov T (2020) Network meta-analysis of efficacy and safety of chlorthalidone and hydrochlorothiazide in hypertensive patients. Blood Press Monit 04:160\u2013168. https:\/\/doi.org\/10.1097\/mbp.0000000000000486","journal-title":"Blood Press Monit"},{"key":"1229_CR93","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejim.2023.05.038","volume":"115","author":"K Ding","year":"2023","unstructured":"Ding K, Li Z, Lu Y, Sun L (2023) Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease. Eur J Intern Med 115:114\u2013127. https:\/\/doi.org\/10.1016\/j.ejim.2023.05.038","journal-title":"Eur J Intern Med"},{"key":"1229_CR94","doi-asserted-by":"publisher","first-page":"1237583","DOI":"10.3389\/fphar.2023.1237583","volume":"14","author":"Y Du","year":"2023","unstructured":"Du Y, Cao G, Gu L, Chen Y, Liu J (2023) Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials. Front Pharmacol 14:1237583. https:\/\/doi.org\/10.3389\/fphar.2023.1237583","journal-title":"Front Pharmacol"},{"issue":"3","key":"1229_CR95","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4103\/ijem.ijem_376_21","volume":"26","author":"D Dutta","year":"2022","unstructured":"Dutta D, Surana V, Bhattacharya S, Aggarwal S, Sharma M (2022) Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: a meta-analysis. Indian J Endocrinol Metab 26(3):198\u2013205. https:\/\/doi.org\/10.4103\/ijem.ijem_376_21","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"1229_CR96","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10741-020-10003-7","volume":"26","author":"PS Eid","year":"2021","unstructured":"Eid PS, Ibrahim DA, Zayan AH, Elrahman MMA, Shehata MAA, Kandil H et al (2021) Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials. Heart Fail Rev 26(1):127\u2013136. https:\/\/doi.org\/10.1007\/s10741-020-10003-7","journal-title":"Heart Fail Rev"},{"issue":"1","key":"1229_CR97","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12872-024-04103-7","volume":"24","author":"A Elshahat","year":"2024","unstructured":"Elshahat A, Mansour A, Ellabban M, Diaa A, Hassan A, Fawzy A et al (2024) Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord 24(1):489. https:\/\/doi.org\/10.1186\/s12872-024-04103-7","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"1229_CR98","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28145","volume":"14","author":"S Faisal","year":"2022","unstructured":"Faisal S, Ahmad Ganaie Z, Batool S, Lokhandwala DHI, Hankins J, Chaudhari SS et al (2022) The efficacy of various pharmacological agents on long-term outcomes in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized control trials. Cureus 14(8):e28145. https:\/\/doi.org\/10.7759\/cureus.28145","journal-title":"Cureus"},{"issue":"5","key":"1229_CR99","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s10557-021-07197-9","volume":"36","author":"IT Farmakis","year":"2022","unstructured":"Farmakis IT, Pyrgidis N, Doundoulakis I, Mykoniatis I, Akrivos E, Giannakoulas G (2022) Effects of major antihypertensive drug classes on erectile function: a network meta-analysis. Cardiovasc Drugs Ther 36(5):903\u2013914. https:\/\/doi.org\/10.1007\/s10557-021-07197-9","journal-title":"Cardiovasc Drugs Ther"},{"key":"1229_CR100","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.amjcard.2023.04.038","volume":"199","author":"K Fatima","year":"2023","unstructured":"Fatima K, Asad D, Shaikh N, Ansari SA, Kumar G, Rehman HA et al (2023) A Systematic review and meta-analysis on effectiveness of mineralocorticoid receptor antagonists in reducing the risk of atrial fibrillation. Am J Cardiol 199:85\u201391. https:\/\/doi.org\/10.1016\/j.amjcard.2023.04.038","journal-title":"Am J Cardiol"},{"issue":"9","key":"1229_CR101","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.cardfail.2018.08.006","volume":"24","author":"BP Fernandes","year":"2018","unstructured":"Fernandes BP, Conceicao LSR, Martins-Filho PRS, de Santana Motta DRM, Carvalho VO (2018) Effect of mineralocorticoid receptor antagonists in individuals with heart failure with preserved ejection fraction: a systematic review. J Card Fail 24(9):618\u2013621. https:\/\/doi.org\/10.1016\/j.cardfail.2018.08.006","journal-title":"J Card Fail"},{"issue":"5","key":"1229_CR102","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.nefroe.2021.04.014","volume":"42","author":"N Ferre","year":"2022","unstructured":"Ferre N, Parada E, Balaguer A, Feliu A, Roque-Figuls M, Franco JVA et al (2022) Pharmacological interventions for preventing complications in patients with idiopathic hypercalciuria: a systematic review. Nefrologia (Engl Ed) 42(5):506\u2013518. https:\/\/doi.org\/10.1016\/j.nefroe.2021.04.014","journal-title":"Nefrologia (Engl Ed)"},{"issue":"2","key":"1229_CR103","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10741-019-09832-y","volume":"25","author":"L Frankenstein","year":"2020","unstructured":"Frankenstein L, Seide S, Tager T, Jensen K, Frohlich H, Clark AL et al (2020) Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. Heart Fail Rev 25(2):161\u2013171. https:\/\/doi.org\/10.1007\/s10741-019-09832-y","journal-title":"Heart Fail Rev"},{"issue":"7","key":"1229_CR104","doi-asserted-by":"publisher","first-page":"7428","DOI":"10.21037\/apm-21-763","volume":"10","author":"Z Fu","year":"2021","unstructured":"Fu Z, Geng X, Chi K, Song C, Wu D, Liu C et al (2021) Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis. Ann Palliat Med 10(7):7428\u20137439. https:\/\/doi.org\/10.21037\/apm-21-763","journal-title":"Ann Palliat Med"},{"issue":"4","key":"1229_CR105","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00380-018-1279-1","volume":"34","author":"H Fukuta","year":"2019","unstructured":"Fukuta H, Goto T, Wakami K, Kamiya T, Ohte N (2019) Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Vessels 34(4):597\u2013606. https:\/\/doi.org\/10.1007\/s00380-018-1279-1","journal-title":"Heart Vessels"},{"key":"1229_CR106","doi-asserted-by":"publisher","first-page":"1114894","DOI":"10.3389\/fendo.2023.1114894","volume":"14","author":"S Ghosal","year":"2023","unstructured":"Ghosal S, Sinha B (2023) Finerenone in type 2 diabetes and renal outcomes: a random-effects model meta-analysis. Front Endocrinol (Lausanne) 14:1114894. https:\/\/doi.org\/10.3389\/fendo.2023.1114894","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1229_CR107","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s13300-022-01359-0","volume":"14","author":"S Ghosal","year":"2023","unstructured":"Ghosal S, Sinha B (2023) Assessing the effects of modern renoprotective agents in preventing progression of renal composite outcomes in patients with type 2 diabetes: a network meta-analysis. Diabetes Therapy 14(2):415\u2013424. https:\/\/doi.org\/10.1007\/s13300-022-01359-0","journal-title":"Diabetes Therapy"},{"issue":"1","key":"1229_CR108","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13098-023-01251-2","volume":"16","author":"X Gu","year":"2024","unstructured":"Gu X, Jiang S, Yang Y, Li W (2024) Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 16(1):14. https:\/\/doi.org\/10.1186\/s13098-023-01251-2","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"1229_CR109","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s11606-020-05731-3","volume":"35","author":"JJ Hall","year":"2020","unstructured":"Hall JJ, Eurich DT, Nagy D, Tjosvold L, Gamble JM (2020) Thiazide diuretic-induced change in fasting plasma glucose: a meta-analysis of randomized clinical trials. J Gen Intern Med 35(6):1849\u20131860. https:\/\/doi.org\/10.1007\/s11606-020-05731-3","journal-title":"J Gen Intern Med"},{"issue":"6","key":"1229_CR110","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1016\/j.amjmed.2019.11.015","volume":"133","author":"MR Hansen","year":"2020","unstructured":"Hansen MR, Hrobjartsson A, Videbaek L, Ennis ZN, Pareek M, Paulsen NH et al (2020) Postponement of death by pharmacological heart failure treatment: a meta-analysis of randomized clinical trials. Am J Med 133(6):e280\u2013e289. https:\/\/doi.org\/10.1016\/j.amjmed.2019.11.015","journal-title":"Am J Med"},{"key":"1229_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.11.026","author":"J Harrington","year":"2023","unstructured":"Harrington J, Fonarow GC, Khan MS, Hernandez A, Anker S, Bohm M et al (2023) Medication-attributable adverse events in heart failure trials. JACC Heart Fail. https:\/\/doi.org\/10.1016\/j.jchf.2022.11.026","journal-title":"JACC Heart Fail"},{"key":"1229_CR112","doi-asserted-by":"publisher","first-page":"CD013109","DOI":"10.1002\/14651858.cd013109.pub2","volume":"2","author":"T Hasegawa","year":"2021","unstructured":"Hasegawa T, Nishiwaki H, Ota E, Levack WM, Noma H (2021) Aldosterone antagonists for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2:CD013109. https:\/\/doi.org\/10.1002\/14651858.cd013109.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1229_CR113","doi-asserted-by":"publisher","first-page":"204062232412397","DOI":"10.1177\/20406223241239775","volume":"15","author":"WY Ho","year":"2024","unstructured":"Ho WY, Hsiao CC, Wu PH, Chen JY, Tu YK, Wu VC et al (2024) Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis. Ther Adv Chronic Dis 15:20406223241239776. https:\/\/doi.org\/10.1177\/20406223241239775","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"1229_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265642","volume":"17","author":"H Hu","year":"2022","unstructured":"Hu H, Zhao X, Jin X, Wang S, Liang W, Cong X (2022) Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: a meta-analysis. PLoS ONE 17(3):e0265642. https:\/\/doi.org\/10.1371\/journal.pone.0265642","journal-title":"PLoS ONE"},{"key":"1229_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.896947","volume":"13","author":"X Jiang","year":"2022","unstructured":"Jiang X, Zhang Z, Li C, Zhang S, Su Q, Yang S et al (2022) Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: a systematic review incorporating an indirect comparisons meta-analysis. Front Pharmacol 13:896947. https:\/\/doi.org\/10.3389\/fphar.2022.896947","journal-title":"Front Pharmacol"},{"issue":"7","key":"1229_CR116","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41746","volume":"15","author":"F Jyotsna","year":"2023","unstructured":"Jyotsna F, Mahfooz K, Patel T, Parshant F, Simran F, Harsha F et al (2023) A systematic review and meta-analysis on the efficacy and safety of finerenone therapy in patients with cardiovascular and chronic kidney diseases in type 2 diabetes mellitus. Cureus 15(7):e41746. https:\/\/doi.org\/10.7759\/cureus.41746","journal-title":"Cureus"},{"issue":"3","key":"1229_CR117","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10741-018-9758-0","volume":"24","author":"CJ Kapelios","year":"2019","unstructured":"Kapelios CJ, Murrow JR, Nuhrenberg TG, Montoro Lopez MN (2019) Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev 24(3):367\u2013377. https:\/\/doi.org\/10.1007\/s10741-018-9758-0","journal-title":"Heart Fail Rev"},{"issue":"9","key":"1229_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102742","volume":"49","author":"P Karakasis","year":"2024","unstructured":"Karakasis P, Patoulias D, Popovic DS, Pamporis K, Theofilis P, Nasoufidou A et al (2024) Effects of mineralocorticoid receptor antagonists on new-onset or recurrent atrial fibrillation: a Bayesian and frequentist network meta-analysis of randomized trials. Curr Probl Cardiol 49(9):102742. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102742","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"1229_CR119","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.japh.2019.01.014","volume":"59","author":"K Kido","year":"2019","unstructured":"Kido K, Shimizu M, Hashiguchi M (2019) Comparing torsemide versus furosemide in patients with heart failure: a meta-analysis. J Am Pharm Assoc (2003) 59(3):432\u2013438. https:\/\/doi.org\/10.1016\/j.japh.2019.01.014","journal-title":"J Am Pharm Assoc (2003)"},{"key":"1229_CR120","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/iju.15608","volume":"16","author":"Y Kohjimoto","year":"2024","unstructured":"Kohjimoto Y, Iba A, Yamashita S, Higuchi M, Deguchi R, Chikazawa I et al (2024) Pharmacotherapy for patients with calcium oxalate stones and abnormal urine chemistry: a systematic review and meta-analysis for the Japanese clinical practice guidelines for the management of urinary stones, third edition. Int J Urol 16:16. https:\/\/doi.org\/10.1111\/iju.15608","journal-title":"Int J Urol"},{"issue":"1","key":"1229_CR121","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12967-020-02270-7","volume":"18","author":"DF Li","year":"2020","unstructured":"Li DF, Gao YL, Liu HC, Huang XC, Zhu RF, Zhu CT (2020) Use of thiazide diuretics for the prevention of recurrent kidney calculi: a systematic review and meta-analysis. J Transl Med 18(1):106. https:\/\/doi.org\/10.1186\/s12967-020-02270-7","journal-title":"J Transl Med"},{"key":"1229_CR122","doi-asserted-by":"publisher","first-page":"1078686","DOI":"10.3389\/fendo.2022.1078686","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Wu H, Peng H, Jiang H (2022) Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: a network meta-analysis. Front Endocrinol (Lausanne) 13:1078686. https:\/\/doi.org\/10.3389\/fendo.2022.1078686","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1229_CR123","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/ejhf.3208","volume":"26","author":"J Li","year":"2024","unstructured":"Li J, Chen Y, Wang Y, Liu X, Li P, He Y et al (2024) Impact of guideline-directed medical therapy on systolic blood pressure and cardiovascular outcomes in patients with heart failure and low blood pressure: a systematic review and meta-analysis. Eur J Heart Fail 26(6):1435\u20131442. https:\/\/doi.org\/10.1002\/ejhf.3208","journal-title":"Eur J Heart Fail"},{"key":"1229_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.828189","volume":"9","author":"J Liu","year":"2022","unstructured":"Liu J, Jia W, Yu C (2022) Safety and efficacy of spironolactone in dialysis-dependent patients: meta-analysis of randomized controlled trials. Front Med (Lausanne) 9:828189. https:\/\/doi.org\/10.3389\/fmed.2022.828189","journal-title":"Front Med (Lausanne)"},{"key":"1229_CR125","doi-asserted-by":"publisher","first-page":"CD012466","DOI":"10.1002\/14651858.cd012466.pub2","volume":"2","author":"M Lunney","year":"2020","unstructured":"Lunney M, Ruospo M, Natale P, Quinn RR, Ronksley PE, Konstantinidis I et al (2020) Pharmacological interventions for heart failure in people with chronic kidney disease. Cochrane Database Syst Rev 2:CD012466. https:\/\/doi.org\/10.1002\/14651858.cd012466.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1229_CR126","doi-asserted-by":"publisher","first-page":"6670183","DOI":"10.1155\/2021\/6670183","volume":"2021","author":"L Ma","year":"2021","unstructured":"Ma L, Zheng K, Yan J, Cheng W (2021) Efficacy of ARB\/HCTZ combination therapy in uncontrolled hypertensive patients compared with ARB monotherapy: a meta-analysis. Int J Hypertens 2021:6670183. https:\/\/doi.org\/10.1155\/2021\/6670183","journal-title":"Int J Hypertens"},{"issue":"2","key":"1229_CR127","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bcp.13787","volume":"85","author":"TV Macfarlane","year":"2019","unstructured":"Macfarlane TV, Pigazzani F, Flynn RWV, MacDonald TM (2019) The effect of indapamide vs. bendroflumethiazide for primary hypertension: a systematic review. Br J Clin Pharmacol 85(2):285\u2013303. https:\/\/doi.org\/10.1111\/bcp.13787","journal-title":"Br J Clin Pharmacol"},{"key":"1229_CR128","doi-asserted-by":"publisher","first-page":"CD012721","DOI":"10.1002\/14651858.cd012721.pub3","volume":"5","author":"N Martin","year":"2021","unstructured":"Martin N, Manoharan K, Davies C, Lumbers RT (2021) Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev 5:CD012721. https:\/\/doi.org\/10.1002\/14651858.cd012721.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"1229_CR129","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1097\/hjh.0000000000003436","volume":"41","author":"VM Martins","year":"2023","unstructured":"Martins VM, Ziegelmann PK, Ferrari F, Bottino LG, Lucca MB, Correa HLR et al (2023) Thiazide diuretics alone or combined with potassium-sparing diuretics to treat hypertension: a systematic review and network meta-analysis of randomized controlled trials. J Hypertens 41(7):1108\u20131116. https:\/\/doi.org\/10.1097\/hjh.0000000000003436","journal-title":"J Hypertens"},{"issue":"6","key":"1229_CR130","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2459\/jcm.0000000000000794","volume":"20","author":"JA Miles","year":"2019","unstructured":"Miles JA, Hanumanthu BK, Patel K, Chen M, Siegel RM, Kokkinidis DG (2019) Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis. J Cardiovasc Med (Hagerstown) 20(6):379\u2013388. https:\/\/doi.org\/10.2459\/jcm.0000000000000794","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"1229_CR131","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14976","author":"R Morita","year":"2023","unstructured":"Morita R, Tsukamoto S, Obata S, Yamada T, Uneda K, Uehara T et al (2023) Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/dom.14976","journal-title":"Diabetes Obes Metab"},{"key":"1229_CR132","doi-asserted-by":"publisher","first-page":"08","DOI":"10.1111\/dom.15009","volume":"08","author":"BN Nguyen","year":"2023","unstructured":"Nguyen BN, Nguyen L, Mital S, Bugden S, Nguyen HV (2023) Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: a systematic review and network meta-anal. Diabetes Obes Metab 08:08. https:\/\/doi.org\/10.1111\/dom.15009","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1229_CR133","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/2047487319879786","volume":"27","author":"C Noone","year":"2020","unstructured":"Noone C, Leahy J, Morrissey EC, Newell J, Newell M, Dwyer CP et al (2020) Comparative efficacy of exercise and anti-hypertensive pharmacological interventions in reducing blood pressure in people with hypertension: a network meta-analysis. Eur J Prev Cardiol 27(3):247\u2013255. https:\/\/doi.org\/10.1177\/2047487319879786","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"1229_CR134","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/eurheartj\/ehad811","volume":"45","author":"A Oraii","year":"2024","unstructured":"Oraii A, Healey JS, Kowalik K, Pandey AK, Benz AP, Wong JA et al (2024) Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials. Eur Heart J 45(10):756\u2013774. https:\/\/doi.org\/10.1093\/eurheartj\/ehad811","journal-title":"Eur Heart J"},{"issue":"7","key":"1229_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102615","volume":"49","author":"K Pamporis","year":"2024","unstructured":"Pamporis K, Karakasis P, Sagris M, Zarifis I, Bougioukas KI, Pagkalidou E et al (2024) Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials. Curr Probl Cardiol 49(7):102615. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102615","journal-title":"Curr Probl Cardiol"},{"key":"1229_CR136","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.amjcard.2021.07.011","volume":"157","author":"D Patoulias","year":"2021","unstructured":"Patoulias D, Papadopoulos C, Toumpourleka M, Doumas M (2021) Meta-analysis addressing the effect of mineralcorticoid receptor antagonists on the risk for new-onset atrial fibrillation. Am J Cardiol 157:150\u2013152. https:\/\/doi.org\/10.1016\/j.amjcard.2021.07.011","journal-title":"Am J Cardiol"},{"issue":"1","key":"1229_CR137","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3803\/enm.2021.1296","volume":"37","author":"D Patoulias","year":"2022","unstructured":"Patoulias D, Papadopoulos C, Karagiannis A, Vassilikos V, Doumas M (2022) Cardiovascular outcomes with finerenone according to glycemic status at baseline and prior treatment with newer antidiabetics among patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul) 37(1):170\u2013174. https:\/\/doi.org\/10.3803\/enm.2021.1296","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1229_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/wnl.0000000000008732","volume":"11","author":"R Peters","year":"2019","unstructured":"Peters R, Yasar S, Anderson CS, Andrews S, Antikainen R, Arima H et al (2019) An investigation of anti-hypertensive class, dementia, and cognitive decline: a meta-analysis. Neurology 11:1\u201315. https:\/\/doi.org\/10.1212\/wnl.0000000000008732","journal-title":"Neurology"},{"issue":"6","key":"1229_CR139","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s00392-023-02349-3","volume":"113","author":"T Sampaio Rodrigues","year":"2024","unstructured":"Sampaio Rodrigues T, Garcia Quarto LJ, Nogueira SC, Koshy AN, Mahajan R, Sanders P et al (2024) Incidence and progression of atrial fibrillation in patients with and without heart failure using mineralocorticoid receptor antagonists: a meta-analysis. Clin Res Cardiol 113(6):884\u2013897. https:\/\/doi.org\/10.1007\/s00392-023-02349-3","journal-title":"Clin Res Cardiol"},{"key":"1229_CR140","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074068","author":"Q Shi","year":"2023","unstructured":"Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Ryden L et al (2023) Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. https:\/\/doi.org\/10.1136\/bmj-2022-074068","journal-title":"BMJ"},{"issue":"11","key":"1229_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101927","volume":"48","author":"AK Siddiqi","year":"2023","unstructured":"Siddiqi AK, Javaid H, Ahmed M, Dhawadi S, Batool L, Zahid M et al (2023) Clinical outcomes with furosemide versus torsemide in patients with heart failure: an updated systematic review and meta-analysis. Curr Probl Cardiol 48(11):101927. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101927","journal-title":"Curr Probl Cardiol"},{"key":"1229_CR142","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.amjcard.2023.08.079","volume":"206","author":"S Singh","year":"2023","unstructured":"Singh S, Goel S, Duhan S, Chaudhary R, Garg A, Tantry US et al (2023) Effect of furosemide versus torsemide on hospitalizations and mortality in patients with heart failure: a meta-analysis of randomized controlled trials. Am J Cardiol 206:42\u201348. https:\/\/doi.org\/10.1016\/j.amjcard.2023.08.079","journal-title":"Am J Cardiol"},{"issue":"2","key":"1229_CR143","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/crd.0000000000000484","volume":"32","author":"J Sreenivasan","year":"2024","unstructured":"Sreenivasan J, Malik A, Khan MS, Lloji A, Hooda U, Aronow WS et al (2024) Pharmacotherapies in heart failure with preserved ejection fraction: a systematic review and network meta-analysis. Cardiol Rev 32(2):114\u2013123. https:\/\/doi.org\/10.1097\/crd.0000000000000484","journal-title":"Cardiol Rev"},{"key":"1229_CR144","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/crd.0000000000000484","volume":"27","author":"J Sreenivasan","year":"2022","unstructured":"Sreenivasan J, Malik A, Khan MS, Lloji A, Hooda U, Aronow WS et al (2022) Pharmacotherapies in heart failure with preserved ejection fraction: a systematic review and network meta-analysis. Cardiol Rev 27:27. https:\/\/doi.org\/10.1097\/crd.0000000000000484","journal-title":"Cardiol Rev"},{"issue":"4","key":"1229_CR145","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10741-019-09771-8","volume":"24","author":"T Tager","year":"2019","unstructured":"Tager T, Frohlich H, Seiz M, Katus HA, Frankenstein L (2019) READY: relative efficacy of loop diuretics in patients with chronic systolic heart failure\u2014a systematic review and network meta-analysis of randomised trials. Heart Fail Rev 24(4):461\u2013472. https:\/\/doi.org\/10.1007\/s10741-019-09771-8","journal-title":"Heart Fail Rev"},{"issue":"6","key":"1229_CR146","doi-asserted-by":"publisher","DOI":"10.36660\/abc.20230825i10.36660\/abc.20230825","volume":"121","author":"L Teixeira","year":"2024","unstructured":"Teixeira L, Felix N, Navalha DDP, Ferreira R, Clemente MRC, Madeira T et al (2024) Torsemide versus furosemide in the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials. Arq Bras Cardiol 121(6):e20230825. https:\/\/doi.org\/10.36660\/abc.20230825i10.36660\/abc.20230825","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"1229_CR147","doi-asserted-by":"publisher","first-page":"2163903","DOI":"10.1080\/0886022x.2022.2163903","volume":"45","author":"F Teles","year":"2023","unstructured":"Teles F, Pecanha de Miranda Coelho JA, Albino RM, Vercosa Pacheco FC, Rodrigues de Oliveira E, Silveira MAD et al (2023) Effectiveness of thiazide and thiazide-like diuretics in advanced chronic kidney disease: a systematic review and meta-analysis. Ren Fail 45(1):2163903. https:\/\/doi.org\/10.1080\/0886022x.2022.2163903","journal-title":"Ren Fail"},{"issue":"1","key":"1229_CR148","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/cvr\/cvad165","volume":"120","author":"Z Tian","year":"2024","unstructured":"Tian Z, Barbosa CV, Lang H, Bauersachs J, Melk A, Schmidt BMW (2024) Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis. Cardiovasc Res 120(1):108\u2013119. https:\/\/doi.org\/10.1093\/cvr\/cvad165","journal-title":"Cardiovasc Res"},{"key":"1229_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110161","volume":"194","author":"S Tsukamoto","year":"2022","unstructured":"Tsukamoto S, Morita R, Yamada T, Urate S, Azushima K, Uneda K et al (2022) Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. Diabetes Res Clin Pract 194:110161. https:\/\/doi.org\/10.1016\/j.diabres.2022.110161","journal-title":"Diabetes Res Clin Pract"},{"key":"1229_CR150","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-022-10275-1","author":"N Wang","year":"2022","unstructured":"Wang N, Evans J, Sawant S, Sindone J, Lal S (2022) Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients. Heart Fail Rev. https:\/\/doi.org\/10.1007\/s10741-022-10275-1","journal-title":"Heart Fail Rev"},{"issue":"2","key":"1229_CR151","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.21618","volume":"3","author":"J Wei","year":"2020","unstructured":"Wei J, Galaviz KI, Kowalski AJ, Magee MJ, Haw JS, Narayan KMV et al (2020) Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Netw 3(2):e1921618. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.21618","journal-title":"JAMA Netw"},{"key":"1229_CR152","doi-asserted-by":"publisher","first-page":"CD001841","DOI":"10.1002\/14651858.cd001841.pub3","volume":"4","author":"JM Wright","year":"2018","unstructured":"Wright JM, Musini VM, Gill R (2018) First-line drugs for hypertension. Cochrane Database Syst Rev 4:CD001841. https:\/\/doi.org\/10.1002\/14651858.cd001841.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"1229_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.967317","volume":"13","author":"Y Wu","year":"2022","unstructured":"Wu Y, Lin H, Tao Y, Xu Y, Chen J, Jia Y et al (2022) Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease. Front Pharmacol 13:967317. https:\/\/doi.org\/10.3389\/fphar.2022.967317","journal-title":"Front Pharmacol"},{"issue":"13","key":"1229_CR154","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000014967","volume":"98","author":"Y Xiang","year":"2019","unstructured":"Xiang Y, Shi W, Li Z, Yang Y, Wang SY, Xiang R et al (2019) Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: a meta-analysis of randomized clinical trials. Medicine (Baltimore) 98(13):e14967. https:\/\/doi.org\/10.1097\/md.0000000000014967","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"1229_CR155","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31963","volume":"5","author":"B Xiang","year":"2022","unstructured":"Xiang B, Zhang R, Wu X, Zhou X (2022) Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: a meta-analysis. JAMA Netw 5(9):e2231963. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.31963","journal-title":"JAMA Netw"},{"issue":"6","key":"1229_CR156","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/hjh.0000000000001720","volume":"36","author":"W Xie","year":"2018","unstructured":"Xie W, Zheng F, Evangelou E, Liu O, Yang Z, Chan Q et al (2018) Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis. J Hypertens 36(6):1256\u20131265. https:\/\/doi.org\/10.1097\/hjh.0000000000001720","journal-title":"J Hypertens"},{"issue":"51","key":"1229_CR157","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000013690","volume":"97","author":"Y Xu","year":"2018","unstructured":"Xu Y, Qiu Z, Yang R, Wu Y, Cheng X (2018) Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 97(51):e13690. https:\/\/doi.org\/10.1097\/md.0000000000013690","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"1229_CR158","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13566","volume":"16","author":"X Xu","year":"2024","unstructured":"Xu X, Feng J, Cui Y, Li P, Dong J, Liao L (2024) Renal effects and safety between Asian and non-Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists. J Diabetes 16(6):e13566. https:\/\/doi.org\/10.1111\/1753-0407.13566","journal-title":"J Diabetes"},{"key":"1229_CR159","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.662544","volume":"12","author":"K Yanai","year":"2021","unstructured":"Yanai K, Ishibashi K, Morishita Y (2021) Systematic review and meta-analysis of renin-angiotensin-aldosterone system blocker effects on the development of cardiovascular disease in patients with chronic kidney disease. Front Pharmacol 12:662544. https:\/\/doi.org\/10.3389\/fphar.2021.662544","journal-title":"Front Pharmacol"},{"issue":"5","key":"1229_CR160","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10741-019-09790-5","volume":"24","author":"P Yang","year":"2019","unstructured":"Yang P, Shen W, Chen X, Zhu D, Xu X, Wu T et al (2019) Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials. Heart Fail Rev 24(5):637\u2013646. https:\/\/doi.org\/10.1007\/s10741-019-09790-5","journal-title":"Heart Fail Rev"},{"issue":"11","key":"1229_CR161","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/dom.14801","volume":"24","author":"S Yang","year":"2022","unstructured":"Yang S, Zhao L, Mi Y, He W (2022) Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and ne. Diabetes Obes Metab 24(11):2159\u20132168. https:\/\/doi.org\/10.1111\/dom.14801","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1229_CR162","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/fjc.0000000000001364","volume":"81","author":"S Yang","year":"2023","unstructured":"Yang S, Shen W, Zhang HZ, Wang CX, Yu WQ, Wu QH (2023) Efficacy and safety of finerenone for prevention of cardiovascular events in type 2 diabetes mellitus with chronic kidney disease: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol 81(1):55\u201362. https:\/\/doi.org\/10.1097\/fjc.0000000000001364","journal-title":"J Cardiovasc Pharmacol"},{"key":"1229_CR163","doi-asserted-by":"publisher","first-page":"1429261","DOI":"10.3389\/fendo.2024.1429261","volume":"15","author":"SQ Yang","year":"2024","unstructured":"Yang SQ, Zhao X, Zhang J, Liu H, Wang YH, Wang YG (2024) Comparative efficacy and safety of SGLT2is and ns-MRAs in patients with diabetic kidney disease: a systematic review and network meta-analysis. Front Endocrinol (Lausanne) 15:1429261. https:\/\/doi.org\/10.3389\/fendo.2024.1429261","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1229_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110592","volume":"198","author":"Q Yang","year":"2023","unstructured":"Yang Q, Lang Y, Yang W, Yang F, Yang J, Wu Y et al (2023) Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 198:110592. https:\/\/doi.org\/10.1016\/j.diabres.2023.110592","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"1229_CR165","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1097\/ms9.0000000000001180","volume":"85","author":"F Yasmin","year":"2023","unstructured":"Yasmin F, Aamir M, Najeeb H, Atif AR, Siddiqui AH, Ahsan MN et al (2023) Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis. Ann Med Surg (Lond) 85(10):4973\u20134980. https:\/\/doi.org\/10.1097\/ms9.0000000000001180","journal-title":"Ann Med Surg (Lond)"},{"issue":"4","key":"1229_CR166","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jchf.2023.07.014","volume":"12","author":"S Zafeiropoulos","year":"2024","unstructured":"Zafeiropoulos S, Farmakis IT, Milioglou I, Doundoulakis I, Gorodeski EZ, Konstantinides SV et al (2024) Pharmacological treatments in heart failure with mildly reduced and preserved ejection fraction: systematic review and network meta-analysis. JACC Heart Fail 12(4):616\u2013627. https:\/\/doi.org\/10.1016\/j.jchf.2023.07.014","journal-title":"JACC Heart Fail"},{"key":"1229_CR167","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2147\/dddt.s189454","volume":"13","author":"Q Zeng","year":"2019","unstructured":"Zeng Q, Zhou X, Xu G (2019) Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis. Drug Des Dev Ther 13:1487\u20131499. https:\/\/doi.org\/10.2147\/dddt.s189454","journal-title":"Drug Des Dev Ther"},{"key":"1229_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00929-3","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang J, Jiang L, Wang T, Li Z, Fu X et al (2022) Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetol Metab Syndr. https:\/\/doi.org\/10.1186\/s13098-022-00929-3","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"1229_CR169","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","volume":"21","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W et al (2022) Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol 21(1):232. https:\/\/doi.org\/10.1186\/s12933-022-01676-5","journal-title":"Cardiovasc Diabetol"},{"key":"1229_CR170","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.819327","volume":"13","author":"MZ Zhang","year":"2022","unstructured":"Zhang MZ, Bao W, Zheng QY, Wang YH, Sun LY (2022) Efficacy and safety of finerenone in chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. Front Pharmacol 13:819327. https:\/\/doi.org\/10.3389\/fphar.2022.819327","journal-title":"Front Pharmacol"},{"issue":"1","key":"1229_CR171","doi-asserted-by":"publisher","first-page":"270","DOI":"10.18433\/jpps30146","volume":"22","author":"X Zhao","year":"2019","unstructured":"Zhao X, Ren Y, Li H, Liu X (2019) The effect of diuretics on patients with heart failure: a network meta-analysis: diuretics effect on heart failure patients. J Pharm Pharm Sci 22(1):270\u2013280. https:\/\/doi.org\/10.18433\/jpps30146","journal-title":"J Pharm Pharm Sci"},{"issue":"5","key":"1229_CR172","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","volume":"104","author":"SL Zheng","year":"2018","unstructured":"Zheng SL, Chan FT, Nabeebaccus AA, Shah AM, McDonagh T, Okonko DO et al (2018) Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart 104(5):407\u2013415. https:\/\/doi.org\/10.1136\/heartjnl-2017-311652","journal-title":"Heart"},{"issue":"4","key":"1229_CR173","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000521908","volume":"47","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Ma S, Huang Q, Fang Y, Tan H, Chen Y et al (2022) Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease. Kidney Blood Press Res 47(4):219\u2013228. https:\/\/doi.org\/10.1159\/000521908","journal-title":"Kidney Blood Press Res"},{"key":"1229_CR174","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13940","author":"S Zhu","year":"2020","unstructured":"Zhu S, Li J, Zhao X (2020) Comparative risk of new-onset hyperkalemia for anti-hypertensive drugs in patients with diabetic nephropathy: a Bayesian network meta-analysis. Int J Clin Pract. https:\/\/doi.org\/10.1111\/ijcp.13940","journal-title":"Int J Clin Pract"},{"issue":"8","key":"1229_CR175","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000024882","volume":"100","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Liu Y, Cai R, Zheng D, Liang X, Tao M et al (2021) The safety and efficacy of low-dose mineralocorticoid receptor antagonists in dialysis patients: a meta-analysis. Medicine (Baltimore) 100(8):e24882. https:\/\/doi.org\/10.1097\/md.0000000000024882","journal-title":"Medicine (Baltimore)"},{"key":"1229_CR176","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-022-03432-w","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Song M, Chen T, Yang Z, Liu Y (2022) Effect of finerenone on cardiovascular events in kidney disease and\/or diabetes: a meta analysis of randomized control trials. Int Urol Nephrol. https:\/\/doi.org\/10.1007\/s11255-022-03432-w","journal-title":"Int Urol Nephrol"},{"key":"1229_CR177","doi-asserted-by":"publisher","first-page":"CD007858","DOI":"10.1002\/14651858.cd007858.pub2","volume":"7","author":"TP Zonneveld","year":"2018","unstructured":"Zonneveld TP, Richard E, Vergouwen MD, Nederkoorn PJ, de Haan R, Roos YB et al (2018) Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 7:CD007858. https:\/\/doi.org\/10.1002\/14651858.cd007858.pub2","journal-title":"Cochrane Database Syst Rev"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-025-01229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-025-01229-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-025-01229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:32:17Z","timestamp":1757172737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-025-01229-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":177,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s41999-025-01229-5","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Min Ji Kwak received a research grant from the US Deprescribing Research Network, receives consult fees from Novo Nordisk, and owns stocks in Eli Lilly and Novo Nordisk. Louis Handoko is supported by a research grant of the Dutch Heart Foundation (NHS; 2020T058), the Amsterdam Cardiovascular Sciences (ACS) Institute, The Netherlands Organization for Scientific Research (NWO), and funding for an investigator-initiated study of Vifor Pharma. He received an educational grant and\/or speaker\/consultancy fees from Novartis, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, AstraZeneca, Bayer, MSD, and Abbott; all not related to this work. Parag Goyal is supported by National Institute on Aging grants K76AG064428 and R21AG077092. Dr. Goyal was a member of the Junior Investigator Intensive Program of the US Deprescribing Research Network and is supported by a US Deprescribing Research Pilot Grant, which are funded by the National Institute on Aging (R24AG064025). He has received consulting fees from Sensorum Health, Agepha Pharma, and Axon therapies; and has received personal fees for medicolegal consulting and expert testimony related to HF. Jerzy G\u0105sowski has given talks on the topic of anti-hypertensive therapy in older persons and deprescribing, some of which were associated with lecture fees. Wade Thompson has received grants for deprescribing research from Health Canada and the National Institute on Aging (US), is supported by a salary award from Michael Smith Health Research British Columbia; and receives an honorarium for writing an article on deprescribing in Pharmacy Practice Plus magazine. Eva Topinkova work was partly supported by the Project New Technologies in Translational Research in Pharmaceutical Sciences\/NETPHARM reg. No. CZ.02.01.01\/00\/22_008\/0004607, co-financed by the European Union. George Soulis has received consulting fees by Reckitt Benckiser for Advisory Board. All other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}